Japan Tobacco/Roche Dyslipidemia Drug Poses Blockbuster Potential - JT Senior Executive
This article was originally published in PharmAsia News
Japanese industry conglomerate Japan Tobacco Senior Executive VP and pharmaceutical business President Noriaki Okubo said the company's dyslipidemia drug candidate, cholesterol ester transfer protein inhibitor JTT-705 could grow to be a ¥100 billion blockbuster drug
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.
"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?"